Thus, our study reveals a novel mechanism by which D-mannose controls TFE3-mediated activation of lysosomal function and VEGFR2 degradation to inhibit angiogenesis and tumor growth in CRC, providing an experimental basis for the potential application of D-mannose in the clinical treatment of CRC. The gene discussed is TFE3; the disease is neoplasm.